Skip to main content

Table 2 Basal characteristics according to level of HbA1c

From: Lack of correlation between the optimal glycaemic control and coronary micro vascular dysfunction in patients with diabetes mellitus: a cross sectional study

  HBA1c > 7 (n 53) HBA1c < 7 (n 47) p value
Age (year) 55 (49–61) 54 (47–61) 0.45
BSA (m2) 2.04 ± 0.25 2.09 ± 0.25 0.40
BMI (kg/m2) 33.95 ± 6.59 34.73 ± 8.42 0.63
Female sex (%) 58.5 63,9 0.54
GFR c–c (ml/min) 108.0 (81.4–144.2) 117.7 (89.2–136.5) 0.79
GFR MRDR (ml/min) 75.9 (62.1–92.8) 71.9 (64.3–83.7) 0.23
Risk factors and CAD history (%)
 Current smoker (%) 13.2 4.2 0.16
 Hypertension (%) 57.7 82.9 <0.01
 Hyperlipidemia (%) 75.0 82.9 0.33
 HDL (mg/dl) 45.0 (37.0–54.5) 45.5 (39.0–54.0) 0.83
 Triglycerides (mg/dl) 160.0 (98.0–230.0) 118.5 (86.7–159.5) <0.05
Inflammatory markers
 Lpa (mg/dl) 14.0 (7.0–35.0) 13.0 (7.0–40.0) 0.74
 hsCrP (mg/l) 1.0 (0.4–4.0) 1.0 (0.4–3.7) 0.31
 Homocysteine (µmol/l) 8.0 (6.0–9.0) 8.0 (6.0–10.0) 0.30
Coronary epicardial and microvascular function
 CFR 2.8 (2.3–3.6) 2.8 (2.4–3.4) 0.55
 CRF < 2.5 (%) 39.6 29.8 0.53
 CBF%Ach 27.4 (−16.6 to 67.4) 15.2 (−28.2 to 69.1) 0.79
 CBFAch < 50 % (%) 62.2 61.7 1.00
 CLD%Ach −10.0 (−24.8 to −3.4) −12.5 (−31.8 to 0.0) 0.93
 CLDAch < 20 % (%) 28.3 36.1 0.52
 CBFbasal 52.9 (33.5–70.4) 51.2 (38.0–73.1) 0.45
 LVEDP (mmHG) 18.0 (12.2–24.7) 17.0 (15.0–22.0) 0.71
Diabetes status and treatment characterization
 DM duration (months) 60.0 (24.0–100.0) 41.0 (8.0–90.0) 0.22
 Fasting glucose (mg/dl) 148.0 (118.0–179.0) 125.0 (103.7–141.0) <0.01
 Insulin (µIU/ml) 14.0 (6.9–20.6) 10.0 (5.1–18.0) 0.47
 DM family history (%) 60.4 47.7 0.29
 Insulin therapy (%) 33.9 21.2 0.18
 Metformin (%) 44.2 44.4 1.00
 Metformin only (%) 28.8 35.5 0.66
 Insulin releasing (%) 28.8 22.7 0.49
Medication (%)
 BBlockers 35.8 46.8 0.31
 CC blockers 28.3 36.1 0.29
 Nitrates 33.9 57.4 <0.05
 ACE/ARB inhibitor 30.1 38.3 0.53
 Lipid lowering 40.1 70.2 <0.05
  1. BMI body mass index, BSA body surface area, GFR cc Cockroft–Gault glomerular filtrate rate, ACS acute coronary syndrome, CAD coronary artery disease, Lpa lipoprotein A, hsCrP high sensitive C reactive protein, CFR coronary flow reserve, CMD coronary microvascular dysfunction, CFR < 2.5 independent CMD, CBF%Ach percentage of increase in CBF after acetylcholine infusion, CBFAch < 50 % dependent CMD, CLD%Ach percentage of increase in coronary lumen diameter after acetylcholine infusion, CLDAch < 20 % epicardial endothelial dysfunction, LVEDP left ventricular end-diastolic pressure, CC blockers calcium channel blocker, ACE/ARB inhibitor angiotensin-converting enzyme/angiotensin inhibitor.